Suppr超能文献

胰腺癌辅助治疗时间与生存关系的重要性:系统评价和荟萃分析。

The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis.

机构信息

Department of Surgery, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.

Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

出版信息

Cancer Rep (Hoboken). 2021 Oct;4(5):e1390. doi: 10.1002/cnr2.1390. Epub 2021 Jul 10.

Abstract

BACKGROUND

While adjuvant chemotherapy benefits patients with pancreatic ductal adenocarcinoma (PDAC), the importance of the time to initiation of adjuvant therapy remains unclear.

AIM

This study seeks to better understand whether the timing of postoperative chemotherapy initiation affects long-term outcomes in PDAC.

METHODS AND RESULTS

A systematic literature search was performed in Medline, Embase, and Cochrane Library in March 2020. Studies focused on the association between the timing of adjuvant therapy on long-term outcomes in resected PDAC patients were included. The impact of early and delayed therapy as defined by the respective studies was evaluated using forest plot analysis. Overall survival (OS) and disease-free survival (DFS) served as primary endpoints. Out of 3099 published articles, 10 retrospective studies met inclusion criteria. Combined, these studies included clinical data of 13 344 patients. The cut off used to define "early" and "delayed" treatment groups varied in the included studies ranging from 3 to 12 weeks. Due to this heterogeneity, a sub-group analysis of three time cut offs was performed: 3 to 5 weeks, 6 to 8 weeks, and 9 to 12 weeks. There was a significant decrease in OS and DFS when adjuvant therapy was delayed by 3 to 5 weeks after surgery (OS, pooled hazard ratio [HR] = 1.86, 95% confidence interval [CI] = 1.25-2.78; DFS, pooled HR = 1.62, 95% CI = 1.12-2.34). However, due to small sample size and limited studies in this subgroup analysis, the results may be indeterminate. There was no significant decrease in OS with delayed initiation of adjuvant therapy by 6 to 8 weeks and 9 to 12 weeks. Similarly, delay in adjuvant therapy beyond 3-5 weeks.

CONCLUSIONS

There was no conclusive evidence suggesting improved survival in patients starting treatment at various time cut offs. Studies investigating the extreme ends of the time-to-treatment spectrum may prove more informative.

摘要

背景

虽然辅助化疗有益于胰腺导管腺癌(PDAC)患者,但辅助治疗开始时间的重要性尚不清楚。

目的

本研究旨在更好地了解术后化疗开始时间是否会影响 PDAC 患者的长期预后。

方法和结果

2020 年 3 月,在 Medline、Embase 和 Cochrane Library 中进行了系统文献检索。纳入了研究辅助治疗时机与接受切除术的 PDAC 患者长期预后之间关联的研究。使用森林图分析评估了各自研究中定义的早期和延迟治疗的影响。总生存期(OS)和无病生存期(DFS)作为主要终点。在 3099 篇已发表的文章中,有 10 项回顾性研究符合纳入标准。这些研究共纳入了 13344 例患者的临床数据。纳入研究中,用于定义“早期”和“晚期”治疗组的截止值各不相同,范围为 3 至 12 周。由于这种异质性,对三个时间截止值进行了亚组分析:3 至 5 周、6 至 8 周和 9 至 12 周。与术后 3 至 5 周开始辅助治疗相比,OS 和 DFS 显著下降(OS,合并风险比[HR]1.86,95%置信区间[CI]1.25-2.78;DFS,合并 HR 1.62,95% CI 1.12-2.34)。然而,由于该亚组分析中样本量小且研究有限,结果可能不确定。辅助治疗延迟 6 至 8 周和 9 至 12 周开始对 OS 无显著影响。同样,辅助治疗延迟超过 3-5 周也没有改善生存。

结论

没有确凿的证据表明在各种时间截止值开始治疗的患者生存得到改善。研究治疗时间范围的极端情况可能会提供更有价值的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c373/8552002/3f66ff22cfc3/CNR2-4-e1390-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验